Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08032560
- Development stage
- Unknown
- Lead developer
- Pfizer
- Administration
- Oral
01
Overview
PF-08032560 is a biologic epigenetic modifier being developed by Pfizer for the treatment of advanced solid tumors. It functions as a selective inhibitor of the histone acetyltransferases KAT6A, KAT6B, and KAT7. These enzymes play a critical role in regulating gene expression by acetylating lysine residues on histone proteins; their overexpression or genetic alteration is linked to oncogenesis in several solid tumor types. PF-08032560 is currently in Phase 1 clinical trials and represents a distinct therapeutic approach from Pfizer's small-molecule KAT6 inhibitor, PF-07248144, which is primarily focused on breast cancer.
02
Targets
KAT7 (Lysine acetyltransferase 7)KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)
Beyond the preview
Go deeper on PF-08032560.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08032560.